兔 vx2 模型在肝癌中的开发与应用

Executive Industry Relevance

The rabbit VX2 liver tumor model provides a robust preclinical platform for evaluating local regional therapies in interventional oncology and radiology. Its reproducible tumor induction and angiographic accessibility enable translational research that bridges discovery and preclinical validation. This model supports enterprise R&D by facilitating the assessment of interventional techniques in a disease-relevant system.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of therapeutic hypotheses for liver cancer interventions.
• Supports biological de-risking by providing a consistent in vivo tumor environment.
• Facilitates functional validation of interventional targets and delivery methods.

Screening & Assay Development

• Prepares a validated animal system for evaluating intra-arterial therapies and device performance.
• Supports reproducibility and standardization of angiographic and therapeutic procedures.
• Enables quantitative assessment of tumor response to localized interventions.

Translational & Preclinical Research

• Aligns with disease-relevant biology for translational biomarker and imaging studies.
• Provides continuity from discovery-stage hypotheses to preclinical validation of interventional strategies.
• Supports risk-adjusted advancement of local regional therapies toward clinical evaluation.

Pipeline & Workflow Integration

The VX2 rabbit model integrates into the preclinical phase of the oncology discovery continuum, supporting the transition from early discovery to lead identification and preclinical validation of interventional therapies.

• Discovery Biology: Facilitates hypothesis testing for local regional therapy mechanisms in a controlled in vivo setting.
• Screening: Provides a reproducible platform for evaluating angiographic visibility and therapeutic delivery.
• Analytics: Enables quantitative imaging and measurement of tumor growth and response.
• Translational Research: Bridges preclinical findings with disease-relevant endpoints for interventional oncology.
• Enterprise Reuse: Offers a standardized, scalable model for repeated evaluation of diverse interventional modalities.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in local regional therapy outcomes and target engagement.
• Operational Value: Enhances standardization and reproducibility of preclinical interventional studies.
• Strategic Value: Informs go/no-go decisions for advancing interventional oncology assets.
• Portfolio Impact: Supports risk-adjusted prioritization of therapeutic candidates and delivery technologies.

Implementation Considerations

• Requires expertise in surgical implantation and interventional radiology techniques.
• Demands access to fluoroscopic imaging and vascular instrumentation infrastructure.
• Necessitates cross-team standardization of procedural and analytical protocols.
• Adaptation may be needed for different tumor types or therapeutic modalities.
• Model limitations include species-specific biology and technical resource requirements.

Biopharma FAQs